China's biopharmaceutical industry has shown a trend of agglomeration development, with a market scale of nearly 400 billion yuan

[pharmaceutical network market analysis] at present, the global biopharmaceutical industry shows a trend of agglomeration development In recent years, China has also given strong support to the development of biopharmaceutical industry, which has shown a trend of agglomeration development China's biopharmaceutical industry has shown a trend of agglomeration development (photo source: pharmaceutical network) According to data, in 2018, the market size of China's biopharmaceutical industry has exceeded 350 billion yuan, and 9 independently developed class 1 new drugs have been approved for listing According to other data, by 2020, the market scale of China's biomedical industry will be nearly 400 billion yuan As an emerging industry, biomedical industry is closely related to the policies implemented by our country At present, China takes an encouraging and supportive attitude towards biomedicine, whether it is a national long-term plan or a large-scale fund, which puts the development of biomedical technology as a priority project For example, in 2018, Shandong set up a master fund supporting key projects of medical and health industry with a total scale of 10 billion yuan Fujian province requires the province's emerging industry venture capital fund, the Internet Economic sub fund to give priority to the Internet plus medical health project In January 2020, Guangzhou passed several regulations on speeding up the development of biomedical industry in Guangzhou, and "real gold and silver" supported biomedical enterprises with a support fund of up to 150 million yuan In recent years, the state and provinces and cities have focused on supporting the development of biomedical industry In addition, encouraging the listing of Biopharmaceutical Enterprises is an important event in the capital market It is pointed out in the industry that advanced Biopharmaceutical Enterprises can be seen to develop rapidly no matter in science and technology innovation board or in the operation of listed companies themselves "Biopharmaceuticals and even innovative pharmaceutical companies will be the focus of capital attention for a long time in the future." It is understood that in 2019, eight Chinese biomedical companies raised US $2.3 billion through the IPO of the Hong Kong stock exchange, almost 10 times that of European companies in the same period In recent years, the adjustment of institutions and the establishment of the National Health Insurance Bureau and the intensive release of policies to encourage innovative drugs have promoted the innovation and development of China's biomedical industry Changes in policies are forcing biomedical enterprises to accelerate innovation and R & D However, some insiders also pointed out that "the current trend is that there are more and more innovative pharmaceutical enterprises, and the competition is more fierce If the enterprises do not increase the R & D investment in time, they will face the risk of being eliminated by the market." It is understood that the R & D investment of China's pharmaceutical enterprises accounts for only 6% of the world's total, which is far behind that of international enterprises In order to better promote the high-quality development of China's biomedical industry, many enterprises have begun to increase R & D investment Data shows that in recent years, China's drug R & D expenditure has been increasing year by year, and it is expected that the growth rate will be maintained at more than 20% in 2019-2023 Other data shows that from 2015 to 2018, the total R & D expenses of Hengrui Pharmaceutical Co., Ltd were RMB 890 million, RMB 1.18 billion, RMB 1.75 billion and RMB 2.67 billion respectively; the total R & D expenses of Fosun Pharmaceutical Co., Ltd were RMB 830 million, RMB 1.1 billion, RMB 1.53 billion and RMB 2.5 billion respectively; the total R & D expenses of Shanghai Pharmaceutical Co., Ltd were RMB 620 million, RMB 670 million, RMB 836 million and RMB 1.389 billion respectively In recent two years, the domestic drug R & D environment has greatly improved The state has successively issued a number of policies to promote the transformation of scientific research, and encouraged the development of innovative drugs and the transformation and development of pharmaceutical enterprises In 2019, driven by a series of innovation policies, China's pharmaceutical pattern has undergone significant changes, and the third new sector, domestic innovative drugs, has gradually emerged, which has broken the pattern of two major sectors dominated by domestic imitation and import innovation for a long time in recent decades, forming three major sectors: Domestic generic drugs, imported innovative drugs and domestic innovative drugs As a whole, the development quality and market capacity of China's biomedical industry have been steadily improved, and the focus of R & D and capital market has gradually shifted to medical devices and biomedical fields In terms of market, the scale of China's biomedical market is rising rapidly, which is expected to reach 2.5 trillion yuan in 2019, with an annual growth rate of more than 10%, outperforming the world and becoming the main driving force for global market growth